Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,117.23
(
-1.19%
)
News Focus
News Focus
Post# of 257579
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 118983

Thursday, 04/28/2011 4:19:27 AM

Thursday, April 28, 2011 4:19:27 AM

Post# of 257579
SNY’s 1Q11 US Lovenox sales were down 5% to €222M (from €233M in 4Q10): http://en.sanofi-aventis.com/binaries/20110428_Q12011_en_tcm28-31968.pdf (page 15).

At the average exchange rate during 1Q11, the €222M translates into roughly $310M. Since NVS sold $247M of generic Lovenox in 1Q11, we now know that NVS had a 44% share of in-market dollar sales during the quarter, which is consistent with what NVS said on its 1Q11 CC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today